Name: Return on Equity (ROE)

Definition: ROE shows how much profit the company earns for its shareholders based on their invested equity. It’s one of the most watched profitability ratios. A consistently high ROE signals strong management and efficient use of shareholder capital. But artificially high ROE may sometimes be boosted by excessive debt.

Interpretation:
• In '2021', AXGN's return on equity was -24.0%, measuring profitability for shareholders. Industry average for Biotechnology: Electromedical & Electrotherapeutic Apparatus in '2021' stood at -34.4%.
• In '2022', AXGN's return on equity was -27.1%, measuring profitability for shareholders. The decline from '2021' may indicate some operational or financial challenges. Industry average for Biotechnology: Electromedical & Electrotherapeutic Apparatus in '2022' stood at -46.9%. Industry average declined by 12.5% from previous year.
• In '2023', AXGN's return on equity was -22.1%, measuring profitability for shareholders. The increase since '2022' reflects strengthening financial performance. Industry average for Biotechnology: Electromedical & Electrotherapeutic Apparatus in '2023' stood at -47.4%. Industry average declined by 0.6% from previous year.
• In '2024', AXGN's return on equity was -10.0%, measuring profitability for shareholders. The increase since '2023' reflects strengthening financial performance. Industry average for Biotechnology: Electromedical & Electrotherapeutic Apparatus in '2024' stood at -82.5%. Industry average declined by 35.1% from previous year.
Overall, AXGN's return on equity has been volatile but showed an upward trend over the past 4 years.

Formula: ROE = Net Income / Shareholders' Equity

Good Range: 10%-20% desirable for many industries.